Comparison · NCT00247962-22d8ceed
Etanercept vs Sulphasalazine: Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Etanercept vs Sulphasalazine: Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20). Trial comparisons, record NCT00247962-22d8ceed. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00247962-22d8ceed
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.759 | 0.714 | 0.8 | wilson | |
| Risk in group 2 | 0.529 | 0.458 | 0.6 | wilson | |
| Risk difference, group 1 minus group 2 | 0.23 | 0.146 | 0.312 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.43 | 1.24 | 1.66 | log | |
| Odds ratio, group 1 over group 2 | 2.8 | 1.93 | 4.06 | log | |
| Number needed to treat, for one more participant with the outcome on Etanercept than on Sulphasalazine | 4.35 | 3.21 | 6.84 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Etanercept | etanercept 50 mg once weekly | 287 | 378 | OG000 |
| Group 2 | Sulphasalazine | Sulphasalazine (SSZ) titration up to 3 g daily | 99 | 187 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20)
- Description
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) participants ASAS = 4 domains: participant global assessment of disease activity, pain, function, inflammation. ASAS 20 = 20% improvement from baseline and an improvement ≥ 10 units on a 0-100 scale (0=no disease activity; 100=high disease activity) for ≥ 3 domains, and no worsening in remaining domain.
- Time frame
- 16 weeks
- Population
All randomized patients who received at least 1 dose of study drug and had at least 1 post-baseline efficacy evaluation. Last observation carried forward approach (LOCF) used for missing data imputations.
Source ClinicalTrials.gov
Trial
- Title
- Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis
- NCT number
- NCT00247962
- Phases
- PHASE4
- Conditions
- Ankylosing Spondylitis
- Interventions
- etanercept, sulphasalazine (SSZ)
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Results first posted
- 2012-11-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00247962?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00247962-22d8ceed